These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 35173719)

  • 1. Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.
    Zhao X; Yue D; Qian J; Zhang L; Song J; Zhang B; Zhang C; Sun L; Ma Y; Zhang H; Wang C
    Front Immunol; 2022; 13():794217. PubMed ID: 35173719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response.
    Sweeney KJ; Tetzlaff MT; Vega F; Gillenwater A; Zuo Z; Gross N; Nagarajan P; Wargo J; Nelson K; Prieto VG; Torres-Cabala CA; Curry JL
    J Cutan Pathol; 2021 May; 48(5):674-679. PubMed ID: 33399228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
    Yue D; Qian J; Chen Z; Zhang B; Chen P; Zhang L; Li J; Zhang H; Wang C
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
    van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS
    Front Immunol; 2021; 12():793964. PubMed ID: 34987518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
    Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
    Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab.
    Takamori S; Furubayashi N; Taguchi K; Matsubara T; Fujishita T; Ito K; Yamaguchi M; Toyozawa R; Seto T; Negishi T; Nakamura M; Okamoto T
    Thorac Cancer; 2021 Jul; 12(14):2122-2125. PubMed ID: 34002950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.
    Paolini L; Poli C; Blanchard S; Urban T; Croué A; Rousselet MC; Le Roux S; Labarrière N; Jeannin P; Hureaux J
    J Immunother Cancer; 2018 Jun; 6(1):52. PubMed ID: 29898781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma.
    Wakasu S; Tagawa T; Haratake N; Kinoshita F; Oku Y; Ono Y; Takenaka T; Oda Y; Shimokawa M; Mori M
    Cancer Immunol Immunother; 2023 Jun; 72(6):1823-1834. PubMed ID: 36688996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
    Tang Y; Li Y; Zhang L; Tong G; Ou Z; Wang Z; Zhang H; Qiao G
    Thorac Cancer; 2020 Apr; 11(4):1094-1098. PubMed ID: 32077636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcoid-like Reaction Discovered on EBUS-TBNA of Intrathoracic Lymph Nodes During Immunotherapy for Metastatic Melanoma.
    Frohlich M; Wang H; Sakr L
    J Immunother; 2020; 43(2):75-78. PubMed ID: 31567703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of tertiary lymphoid structures on tumor prognosis and the immune microenvironment in non-small cell lung cancer.
    Weng Y; Yuan J; Cui X; Wang J; Chen H; Xu L; Chen X; Peng M; Song Q
    Sci Rep; 2024 Jul; 14(1):16246. PubMed ID: 39009684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
    Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
    BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
    Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
    Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
    [No Abstract]   [Full Text] [Related]  

  • 19. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
    Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma.
    Wang D; Huang L; Qian D; Cao Y; Wu X; Xu P; Ming L; Tang J; Huang Z; Yin Y; Zhou L
    Front Immunol; 2023; 14():1334408. PubMed ID: 38259481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.